{"nct_id":"NCT02159365","title":"Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients","status":"COMPLETED","status_verified_date":"2019-07","start_date":"2014-03-08","start_date_type":"ACTUAL","primary_completion_date":"2016-06-30","primary_completion_date_type":"ACTUAL","completion_date":"2018-07-11","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["BMY"]}